Low level INH-resistant BCG: A sheep in Wolf's clothing?

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 89-93

  Arend, Sandra M ^a   Van Soolingen, Dick ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BCG VACCINE; ETHAMBUTOL; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BCG VACCINATION; BLADDER CANCER; BOVINE TUBERCULOSIS; CANCER IMMUNOTHERAPY; CATHETERIZATION; CELLULAR IMMUNITY; DRUG CONTRAINDICATION; DRUG FEVER; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE DYSREGULATION; INFECTION RISK; MYCOBACTERIUM BOVIS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEPSIS; BIOLOGICAL THERAPY; BLADDER TUMOR; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

ANTITUBERCULAR AGENTS; BIOLOGICAL THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOTHERAPY; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; URINARY BLADDER NEOPLASMS;

EID: 79951590733     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq016     Document Type: Note

References (27)

1. Watts MR, Taylor PC, Sintchenko V, et al. Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. Clin Infect Dis 2011;52:86-88.
2. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006;42:548-558. (Pubitemid 43202529)
3. van de Vosse E, van Dissel JT, Ottenhoff TH. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis 2009;9:688-698.
4. Mak TK, Hesseling AC, Hussey GD, Cotton MF. Making BCG vaccination programmes safer in the HIV era. Lancet 2008;372:786-787.
5. Lamm DL. Efficacy and safety of bacille Calmette-Gurin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3): S86-S90. (Pubitemid 32269596)
6. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000; CD001986.
7. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010;36:195-205.
8. Mostowy S, Tsolaki AG, Small PM, Behr MA. The in vitro evolution of BCG vaccines. Vaccine 2003;21:4270-4274. (Pubitemid 37130272)
9. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-1523.
10. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140-148. (Pubitemid 36143410)
11. van der Meijden PM, van KB, Steerenberg PA, de Boer LC, de Jong WH, Debruyne FM. The possible influence of antibiotics on results of bacillus Calmette-Guerin intravesical therapy for superficial bladder cancer. J Urol 1991;146:444-446.
12. Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Höltl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997;157:1246-1249. (Pubitemid 27130791)
13. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935-939. (Pubitemid 44142611)
14. Durek C, Richter E, Basteck A, et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol 2001;165:1765-1768. (Pubitemid 32410305)
15. Molina JM, Rabian C, D'Agay MF, Modai J. Hypersensitivity systemic reaction following intravesical bacillus Calmette-Guerin: Successful treatment with steroids. J Urol 1992;147:695-697.
16. Durek C, Jurczok A, Werner H, Jocham D, Bohle A. Optimal treatment of systemic bacillus Calmette-Guerin infection: Investigations in an animal model. J Urol 2002;168:826-831. (Pubitemid 34793369)
17. Bilen CY, Inci K, Erkan I, Ozen H. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J Urol 2003;169:1702-1705. (Pubitemid 36443475)
18. Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D. Systemic bacillus Calmette-Guerin infection, "BCGitis", in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 1989;16:161-164. (Pubitemid 19138106)
19. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: A review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990;68:93-108. (Pubitemid 20153776)
20. Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Guerin. Clin Infect Dis 2002;34:447-453. (Pubitemid 34112264)
21. Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997;389:133-134.
22. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guerin disease: implications for management of Bacillus Calmette-Guerin Disease in human immunodeficiency virusinfected children. Pediatr Infect Dis J 2004;23:476-479. (Pubitemid 38621494)
23. WHO. Global Advisory Commitee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec 2005;80:241-248.
24. Knezevic I, Corbel MJ. WHO discussion on the improvement of the quality control of BCG vaccines. Pasteur Institute, Paris, France, 7 June 2005. Vaccine 2006;24:3874-3877.
25. van KB, ssens-Kroon M, van der LT, Kremer K, van SD. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007;45:2662-2668. (Pubitemid 47295501)
26. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53:316-318.
27. Buriankova K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 2004;48:143-150. (Pubitemid 38040190)